Northern Trust’s Insight Molecular Diagnostics IMDX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $161K | Buy |
49,090
+232
| +0.5% | +$1.35K | ﹤0.01% | 3997 |
|
|
2025
Q4 | $366K | Buy |
48,858
+15,968
| +49% | +$90.1K | ﹤0.01% | 3769 |
|
|
2025
Q3 | $109K | Hold |
32,890
| – | – | ﹤0.01% | 4116 |
|
|
2025
Q2 | $99.3K | Buy |
32,890
+3,821
| +13% | +$11.5K | ﹤0.01% | 4112 |
|
|
2025
Q1 | $89K | Buy |
29,069
+11,736
| +68% | +$31.7K | ﹤0.01% | 4142 |
|
|
2024
Q4 | $41.3K | Sell |
17,333
-13
| -0.1% | -$35 | ﹤0.01% | 4285 |
|
|
2024
Q3 | $49.4K | Hold |
17,346
| – | – | ﹤0.01% | 4213 |
|
|
2024
Q2 | $51.2K | Buy |
+17,346
| New | +$47.7K | ﹤0.01% | 4207 |
|
|
2023
Q3 | – | Sell |
-9,746
| Closed | -$44.8K | – | 4508 |
|
|
2023
Q2 | $44.8K | Hold |
9,746
| – | – | ﹤0.01% | 4241 |
|
|
2023
Q1 | $69.1K | Sell |
9,746
-694
| -7% | -$5.15K | ﹤0.01% | 4180 |
|
|
2022
Q4 | $67K | Hold |
10,440
| – | – | ﹤0.01% | 4206 |
|
|
2022
Q3 | $152K | Hold |
10,440
| – | – | ﹤0.01% | 3981 |
|
|
2022
Q2 | $188K | Sell |
10,440
-17,155
| -62% | -$390K | ﹤0.01% | 3959 |
|
|
2022
Q1 | $822K | Sell |
27,595
-1,532
| -5% | -$49K | ﹤0.01% | 3523 |
|
|
2021
Q4 | $1.26M | Sell |
29,127
-619
| -2% | -$35.6K | ﹤0.01% | 3448 |
|
|
2021
Q3 | $2.12M | Sell |
29,746
-10,899
| -27% | -$1M | ﹤0.01% | 3258 |
|
|
2021
Q2 | $4.67M | Buy |
40,645
+3,527
| +10% | +$344K | ﹤0.01% | 2875 |
|
|
2021
Q1 | $3.85M | Buy |
37,118
+3,187
| +9% | +$303K | ﹤0.01% | 2905 |
|
|
2020
Q4 | $1.62M | Buy |
33,931
+638
| +2% | +$23.4K | ﹤0.01% | 3291 |
|
|
2020
Q3 | $926K | Buy |
33,293
+8,591
| +35% | +$246K | ﹤0.01% | 3423 |
|
|
2020
Q2 | $944K | Buy |
24,702
+9,953
| +67% | +$514K | ﹤0.01% | 3380 |
|
|
2020
Q1 | $723K | Buy |
14,749
+2,096
| +17% | +$103K | ﹤0.01% | 3344 |
|
|
2019
Q4 | $569K | Buy |
12,653
+169
| +1% | +$6.1K | ﹤0.01% | 3528 |
|
|
2019
Q3 | $524K | Buy |
12,484
+8,785
| +237% | +$345K | ﹤0.01% | 3527 |
|
|
2019
Q2 | $184K | Buy |
3,699
+905
| +32% | +$75.2K | ﹤0.01% | 3846 |
|
|
2019
Q1 | $220K | Buy |
2,794
+2,050
| +276% | +$132K | ﹤0.01% | 3754 |
|
|
2018
Q4 | $20K | Hold |
744
| – | – | ﹤0.01% | 4152 |
|
|
2018
Q3 | $37K | Buy |
744
+234
| +46% | +$12.1K | ﹤0.01% | 4167 |
|
|
2018
Q2 | $26K | Sell |
510
-1,693
| -77% | -$83.4K | ﹤0.01% | 4194 |
|
|
2018
Q1 | $92K | Buy |
2,203
+1
| +0% | +$66 | ﹤0.01% | 3988 |
|
|
2017
Q4 | $205K | Buy |
2,202
+6
| +0.3% | +$676 | ﹤0.01% | 3810 |
|
|
2017
Q3 | $331K | Buy |
2,196
+159
| +8% | +$16.7K | ﹤0.01% | 3651 |
|
|
2017
Q2 | $211K | Buy |
+2,037
| New | +$232K | ﹤0.01% | 3784 |
|
|
2016
Q2 | – | Sell |
-1,463
| Closed | -$135K | – | 4256 |
|
|
2016
Q1 | $135K | Buy |
+1,463
| New | +$130K | ﹤0.01% | 3842 |
|
Other funds holding IMDX
BC
AIC
PVI
VCM
HCM
FIA
VFT
Northern Trust's IMDX Position: Q1 2026 in Review
Northern Trust increased its Insight Molecular Diagnostics (IMDX) stake by 0.47% in Q1 2026, buying an estimated $1.35K and bringing the position to 49,090 shares worth $161K. The position accounts for ﹤0.01% of the portfolio, ranked #3997.
Northern Trust first reported a position in IMDX in Q1 2016 and has held it in 34 quarters since. The position peaked at $4.67M in Q2 2021. 41 funds tracked by Wall St. Rank hold IMDX as of Q1 2026.
- Northern Trust held 49,090 shares of Insight Molecular Diagnostics worth $161K as of Q1 2026.
- Northern Trust bought 232 Insight Molecular Diagnostics shares in Q1 2026, an estimated $1.35K.
- Insight Molecular Diagnostics made up ﹤0.01% of Northern Trust's portfolio in Q1 2026, its #3997 holding.
- Northern Trust first reported a position in Insight Molecular Diagnostics in Q1 2016 and has held it in 34 quarters since.
- Northern Trust's Insight Molecular Diagnostics position peaked at $4.67M in Q2 2021.
- 41 funds tracked by Wall St. Rank held Insight Molecular Diagnostics as of Q1 2026.
Based on Northern Trust's 13F filing for Q1 2026, filed 14 May 2026.